



## Parameters of Apoptosis and Prevention of Neuro-Like Conditions in Patients with Type II Diabetes Mellitus

**Muhammadjonov Oqilbek,**

Fergana medical Institute of Public Health

**Zokirov Muzaffar**

Fergana medical Institute of Public Health

### ABSTRACT

Neurosis-like states are a group of neuropsychiatric diseases that resemble neuroses in their symptoms, but the occurrence of which is not caused by a stress factor or psychological causes. A neurosis-like syndrome is manifested by such symptoms as lethargy, increased fatigue, distracted attention, general malaise, irritability, irascibility, anger, anxiety, anxiety, and fears. A neurosis-like state is caused not by the very presence of the above diseases, but by the fact that, arising and developing, they lead to disturbances in the functioning of certain brain structures (hypothalamic- limbic), which in turn leads to a disorder in the neurodynamics of the cerebral cortex.

### Keywords:

neurosis-like states, diabetic encephalopathy.

Diabetes mellitus is a disorder in which the concentration of blood glucose is persistently raised above the normal range. It occurs either because of a lack of insulin or because of the presence of factors which oppose the action of insulin. Hyperglycaemia results from insulin action. There are many associated metabolic abnormalities—notably, the development of hyperketonaemia when there is a severe lack of insulin, together with alterations of fatty acids, lipids, and protein turnover. Diabetes is a permanent condition in all but a few special situations in which it can be transient. A wide variety of disturbances affecting the central and peripheral nervous systems, either directly or indirectly, may be encountered in patients with diabetes mellitus. This short selective review concentrates on recent progress in the delineation of the clinical features of the neurological syndromes related to diabetes and their management. It will deal, sequentially, with the classification of diabetes,


a listing of some genetic disorders that may be accompanied by diabetes, the consequences of acute metabolic decompensation, and somatic and autonomic neuropathies, cerebrovascular disease, certain infections that have a particular association with diabetes and, finally, congenital malformations. Questions about relatively persistent mental disorders in patients with diabetes attracted the attention of many authors already in the 19th century, who, in particular, indicated that diabetes mellitus often causes real mental illness. However, later it was established that such an assertion was false. As rightly pointed out in 1954 r. M. Bleuler, patients with diabetes are mentally healthy people, although they, like those who do not have diabetes, may develop mental disorders. According to this author, highly intelligent and energetic people are more likely to be found among diabetic patients than among the rest of the population. A significant frequency of neurotic phenomena

in diabetes (including juvenile diabetes) is reported by many authors, emphasizing the negative role of the unstable course of diabetes and especially numerous hypoglycemia.

**Purpose of the study.** Prevention of neurosis-like conditions in patients with type 2 diabetes mellitus.

**Materials and research methods .** 25 patients with type 2 diabetes mellitus with neurosis-like disorders identified during neurological examination were examined. The study was conducted in the endocrinology department of the ASMI clinic. Of the 25 patients examined by us, the following neurosis-like syndromes were identified: n eurasthenic - in 16 patients ( 64 %), manifested by a hyposthenic form in 4 patients ( 16 %) and hypersthenic - in 12 ( 48 %); and stenodepressive - in 4 patients ( 16 %); n sychasthenic (obsessive states) - in 3 patients ( 12 %); and stenoipochondriacal - in 2 patients ( 8 %). The most common symptoms were: increased irritability (from mild to outbursts of rage), rapid physical and mental fatigue, memory loss, sleep disturbance (often in the form of poor falling asleep, light, shallow and intermittent sleep), difficulty concentrating, a feeling of internal dissatisfaction and resentment, narrowing the range of interests, apathy, lethargy, tearfulness, a tendency to depression, increased anxiety and timidity, obsessive fears. All patients received Magne B6 forte 2 tablets 3 times a day for 2 weeks.

**Results and Discussion .** After taking the drug Magne B6 forte in patients with diabetes mellitus, neurosis-like symptoms looked like this:



neurosis-like syndromes: n eurasthenic - in 12 patients ( 48 %), manifested by a hyposthenic form in 3 patients ( 12 %) and hypersthenic - in 8 ( 32 %); and stenodepressive - in 2 patients ( 8 %); n sychasthenic (obsessive states) - in 2 patients ( 6 %); and stenoipochondriacal - in 1 patient ( 4 %). Decreased irritability, physical and mental fatigue, apathy, lethargy, tearfulness, tendency to depression, increased anxiety and timidity, obsessive fears; normalization of sleep was observed. Also in the observed patients there was a relative normalization of blood pressure and hyperglycemia in the blood.

#### Conclusions:

1. In the occurrence and neurosis-like symptoms in diabetes, the premorbid personality traits of the patient, the type of his higher nervous activity, the severity and duration of the course of diabetes, and the presence of cerebral vascular disorders were important.
2. When patients took the drug Magne B6 forte, neurosis-like symptoms regressed, there was a decrease in blood pressure and relative normalization and maintenance of hyperglycemia at a constant level.
3. By increasing the sensitivity of body tissues to insulin, there was a relative decrease in hyperglycemia in the blood.
4. Prophylactic administration of Magne B6 forte provides the body with the necessary

forces, strengthens the immune system, and increases the body's resistance to everyday stress.

## Literature

1. Зокиров М.М. & Касымова, С. А., & Рустамова, И. К. (2019). Нейропсихологическое исследование пациентов с длительной посттравматической эпилепсией. *Молодой ученый*, (4), 116-118.
2. Sarvinoz, T., & Muzaffar, Z. (2022). Rehabilitation aspects of water therapy in modern medicine. *Uzbek Scholar Journal*, 6, 102-106.
3. Sarvinoz, T., & Muzaffar, Z. (2022). Rehabilitation for childhood cerebral palsy. *Uzbek Scholar Journal*, 6, 97-101.
4. Nabievna, M. Y., & Muzaffar, Z. (2022). Literatural review of the relevance of the problem of neurosaisds. *Modern Journal of Social Sciences and Humanities*, 4, 558-561.
5. Nabievna, M. Y., & Muzaffar, Z. (2022). Modern View on the Pathogenesis of Hiv Encephalopathy. *Spanish Journal of Innovation and Integrity*, 6, 478-481.
6. Muzaffar, Z., & Okilbeck, M. (2022). Dementia and arterial hypertension. *Modern Journal of Social Sciences and Humanities*, 4, 19-23.
7. Muzaffar, Z., (2022). Chronic Obstructive Pulmonary Disease in Combination with Cardiovascular Diseases. *European Multidisciplinary Journal of Modern Science*, 6, 150-155.
8. Зокиров, М., & Мухаммаджонов, О. (2022). Особенности развития тревожных и депрессивных расстройств при заболеваниях, сопровождающихся хроническим болевым синдромом. *Barqarorlik va yetakchi tadqiqotlar onlayn ilmiy jurnali*, 841-844.
9. Зокиров, М., & Мухаммаджонов, О. (2022). Вич энцефалопатия и его патогенетические аспекты. *Barqarorlik va yetakchi tadqiqotlar onlayn ilmiy jurnali*, 855-858.
10. Muzaffar, Z. (2022). HIV Encephalopathy and its Pathogenetic Aspects. *European Multidisciplinary Journal of Modern Science*, 4, 843-846.
11. Зокиров, М. М., Рустамова, И. К., Касимова, С. А., & Кучкарова, О. Б. (2019). Жарохатдан кейинги талвасада кечки нейровизуализацион ўзгаришлар. In *Современная медицина: новые подходы и актуальные исследования* (pp. 56-60).
12. Zokirov M., Mukhammadjonov, O. (2022). Cognitive Impairments in Patients with HIV-Associated Encephalopathy. *Central asian journal of medical and natural sciences*, 3(2), 401-405.
13. Zokirov, M. M., & Mukhammadjonov, O. (2022). Cognitive impairment in patients with Parkinson's disease and optimization of its treatment. *Eurasian Scientific Herald*, 7, 177-180.
14. Зокиров, М., & Туланбоева, С. (2022). Когнитивные нарушений у пациентов с ВИЧ-ассоциированной энцефалопатией. *Barqarorlik va yetakchi tadqiqotlar onlayn ilmiy jurnali*, 68-73.
15. Muzaffar, Z. (2022). Literature reviews on nervous system damage during hiv infection. *Barqarorlik va yetakchi tadqiqotlar onlayn ilmiy jurnali*, 2(9), 141-147.
16. Muzaffar, Z. (2022). Correction of cognitive disorders in patients with hiv encephalopathy. *Web of Scientist: International Scientific Research Journal*, 3(12), 402-411.
17. Muzaffar, Z. (2022). Psychological State in Patients with HIV Infection. *Amaliy va tibbiyot fanlari ilmiy jurnali*, 1(6), 52-56.
18. Зокиров, М., & Мадмаров, Д. (2022). Корреляция ээг картины головного мозга и когнитивного статуса у

- пациентов с эпилепсией. *Theoretical aspects in the formation of pedagogical sciences*, 1(5), 227-230.
19. Зокиров, М. (2021). *Medical sciences. scientific ideas of young scientists*, 21
20. Зокиров, М. (2022). Анализ когнитивных нарушений у пациентов с ВИЧ-энцефалопатией. *Barqarorlik va yetakchi tadqiqotlar onlayn ilmiy jurnali*, 2(10), 251-260.
21. Muhammadjonov, O., & Zokirov, M. 2-toifa qandli diabet bilan og'rigan bemorlarda yurak-qon tomir kasalliklarining xavf omillarining tarqalishi. *Студенческий вестник Учредители: Общество с ограниченной ответственностью "Интернаука" Тематическое направление: Other social sciences*, 53-54.
22. Зокиров М. Коррекция когнитивных нарушений у больных с ВИЧ-ассоциированной энцефалопатией. *Дж. Теор. заявл. науч.* 2021, 7, 62-66. [ [Академия Google](#) ] [ [Перекрестная ссылка](#) ]
23. Zokirov, M. (2023, June). Features of cognitive impairment in patients with HIV encephalopathy. In *Academic International Conference on Multi-Disciplinary Studies and Education* (Vol. 1, No. 9, pp. 34-36).
24. Zokirov, M. M., & Madjidova, Y. N. (2020). Correction Of Cognitive Disorder In Patients With HIV-Associated Encephalopathy. *The American Journal of Medical Sciences and Pharmaceutical Research*, 2(07), 117-122.